Global Duchenne Muscular Dystrophy Therapeutics Market Size, Status and Forecast 2024-2031

Report ID: 954745 | Published Date: Jan 2025 | No. of Page: 108 | Base Year: 2024 | Rating: 3.9 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Pain Management Drugs
        1.2.3 Corticosteroids
        1.2.4 Prednisolone
        1.2.5 Prednisone
        1.2.6 Deflazacort
    1.3 Market by Application
        1.3.1 Global Duchenne Muscular Dystrophy Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Hospitals
        1.3.3 Clinics
        1.3.4 Home Care
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Duchenne Muscular Dystrophy Therapeutics Market Perspective (2016-2027)
    2.2 Duchenne Muscular Dystrophy Therapeutics Growth Trends by Regions
        2.2.1 Duchenne Muscular Dystrophy Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Duchenne Muscular Dystrophy Therapeutics Historic Market Share by Regions (2016-2021)
        2.2.3 Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Regions (2022-2027)
    2.3 Duchenne Muscular Dystrophy Therapeutics Industry Dynamic
        2.3.1 Duchenne Muscular Dystrophy Therapeutics Market Trends
        2.3.2 Duchenne Muscular Dystrophy Therapeutics Market Drivers
        2.3.3 Duchenne Muscular Dystrophy Therapeutics Market Challenges
        2.3.4 Duchenne Muscular Dystrophy Therapeutics Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Duchenne Muscular Dystrophy Therapeutics Players by Revenue
        3.1.1 Global Top Duchenne Muscular Dystrophy Therapeutics Players by Revenue (2016-2021)
        3.1.2 Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Players (2016-2021)
    3.2 Global Duchenne Muscular Dystrophy Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Duchenne Muscular Dystrophy Therapeutics Revenue
    3.4 Global Duchenne Muscular Dystrophy Therapeutics Market Concentration Ratio
        3.4.1 Global Duchenne Muscular Dystrophy Therapeutics Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy Therapeutics Revenue in 2020
    3.5 Duchenne Muscular Dystrophy Therapeutics Key Players Head office and Area Served
    3.6 Key Players Duchenne Muscular Dystrophy Therapeutics Product Solution and Service
    3.7 Date of Enter into Duchenne Muscular Dystrophy Therapeutics Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Duchenne Muscular Dystrophy Therapeutics Breakdown Data by Type
    4.1 Global Duchenne Muscular Dystrophy Therapeutics Historic Market Size by Type (2016-2021)
    4.2 Global Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Type (2022-2027)

5 Duchenne Muscular Dystrophy Therapeutics Breakdown Data by Application
    5.1 Global Duchenne Muscular Dystrophy Therapeutics Historic Market Size by Application (2016-2021)
    5.2 Global Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Duchenne Muscular Dystrophy Therapeutics Market Size (2016-2027)
    6.2 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Type
        6.2.1 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2021)
        6.2.2 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2022-2027)
        6.2.3 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2027)
    6.3 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Application
        6.3.1 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2021)
        6.3.2 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2022-2027)
        6.3.3 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2027)
    6.4 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Country
        6.4.1 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2016-2021)
        6.4.2 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Duchenne Muscular Dystrophy Therapeutics Market Size (2016-2027)
    7.2 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Type
        7.2.1 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2021)
        7.2.2 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2022-2027)
        7.2.3 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2027)
    7.3 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Application
        7.3.1 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2021)
        7.3.2 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2022-2027)
        7.3.3 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2027)
    7.4 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Country
        7.4.1 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2016-2021)
        7.4.2 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size (2016-2027)
    8.2 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Type
        8.2.1 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2027)
    8.3 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Application
        8.3.1 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2027)
    8.4 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Region
        8.4.1 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size (2016-2027)
    9.2 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Type
        9.2.1 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2021)
        9.2.2 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2022-2027)
        9.2.3 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2027)
    9.3 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Application
        9.3.1 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2021)
        9.3.2 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2022-2027)
        9.3.3 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2027)
    9.4 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Country
        9.4.1 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2016-2021)
        9.4.2 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size (2016-2027)
    10.2 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Type
        10.2.1 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2027)
    10.3 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Application
        10.3.1 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2027)
    10.4 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Country
        10.4.1 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Bristol-Myers Squibb
        11.1.1 Bristol-Myers Squibb Company Details
        11.1.2 Bristol-Myers Squibb Business Overview
        11.1.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Introduction
        11.1.4 Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
        11.1.5 Bristol-Myers Squibb Recent Development
    11.2 FibroGen (US)
        11.2.1 FibroGen (US) Company Details
        11.2.2 FibroGen (US) Business Overview
        11.2.3 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Introduction
        11.2.4 FibroGen (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
        11.2.5 FibroGen (US) Recent Development
    11.3 Italfarmaco (Italy)
        11.3.1 Italfarmaco (Italy) Company Details
        11.3.2 Italfarmaco (Italy) Business Overview
        11.3.3 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Introduction
        11.3.4 Italfarmaco (Italy) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
        11.3.5 Italfarmaco (Italy) Recent Development
    11.4 Marathon
        11.4.1 Marathon Company Details
        11.4.2 Marathon Business Overview
        11.4.3 Marathon Duchenne Muscular Dystrophy Therapeutics Introduction
        11.4.4 Marathon Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
        11.4.5 Marathon Recent Development
    11.5 NS Pharma (US)
        11.5.1 NS Pharma (US) Company Details
        11.5.2 NS Pharma (US) Business Overview
        11.5.3 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Introduction
        11.5.4 NS Pharma (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
        11.5.5 NS Pharma (US) Recent Development
    11.6 PTC Therapeutics (US)
        11.6.1 PTC Therapeutics (US) Company Details
        11.6.2 PTC Therapeutics (US) Business Overview
        11.6.3 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Introduction
        11.6.4 PTC Therapeutics (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
        11.6.5 PTC Therapeutics (US) Recent Development
    11.7 Pfizer
        11.7.1 Pfizer Company Details
        11.7.2 Pfizer Business Overview
        11.7.3 Pfizer Duchenne Muscular Dystrophy Therapeutics Introduction
        11.7.4 Pfizer Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
        11.7.5 Pfizer Recent Development
    11.8 ReveraGen BioPharma (US)
        11.8.1 ReveraGen BioPharma (US) Company Details
        11.8.2 ReveraGen BioPharma (US) Business Overview
        11.8.3 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Introduction
        11.8.4 ReveraGen BioPharma (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
        11.8.5 ReveraGen BioPharma (US) Recent Development
    11.9 Santhera Pharmaceuticals (Switzerland)
        11.9.1 Santhera Pharmaceuticals (Switzerland) Company Details
        11.9.2 Santhera Pharmaceuticals (Switzerland) Business Overview
        11.9.3 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Introduction
        11.9.4 Santhera Pharmaceuticals (Switzerland) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
        11.9.5 Santhera Pharmaceuticals (Switzerland) Recent Development
    11.10 Sarepta Therapeutics (US)
        11.10.1 Sarepta Therapeutics (US) Company Details
        11.10.2 Sarepta Therapeutics (US) Business Overview
        11.10.3 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Introduction
        11.10.4 Sarepta Therapeutics (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
        11.10.5 Sarepta Therapeutics (US) Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Duchenne Muscular Dystrophy Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Pain Management Drugs
    Table 3. Key Players of Corticosteroids
    Table 4. Key Players of Prednisolone
    Table 5. Key Players of Prednisone
    Table 6. Key Players of Deflazacort
    Table 7. Global Duchenne Muscular Dystrophy Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 8. Global Duchenne Muscular Dystrophy Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 9. Global Duchenne Muscular Dystrophy Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
    Table 10. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Regions (2016-2021)
    Table 11. Global Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 12. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Regions (2022-2027)
    Table 13. Duchenne Muscular Dystrophy Therapeutics Market Trends
    Table 14. Duchenne Muscular Dystrophy Therapeutics Market Drivers
    Table 15. Duchenne Muscular Dystrophy Therapeutics Market Challenges
    Table 16. Duchenne Muscular Dystrophy Therapeutics Market Restraints
    Table 17. Global Duchenne Muscular Dystrophy Therapeutics Revenue by Players (2016-2021) & (US$ Million)
    Table 18. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Players (2016-2021)
    Table 19. Global Top Duchenne Muscular Dystrophy Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Duchenne Muscular Dystrophy Therapeutics as of 2020)
    Table 20. Ranking of Global Top Duchenne Muscular Dystrophy Therapeutics Companies by Revenue (US$ Million) in 2020
    Table 21. Global 5 Largest Players Market Share by Duchenne Muscular Dystrophy Therapeutics Revenue (CR5 and HHI) & (2016-2021)
    Table 22. Key Players Headquarters and Area Served
    Table 23. Key Players Duchenne Muscular Dystrophy Therapeutics Product Solution and Service
    Table 24. Date of Enter into Duchenne Muscular Dystrophy Therapeutics Market
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 27. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Type (2016-2021)
    Table 28. Global Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 29. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 30. Global Duchenne Muscular Dystrophy Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
    Table 31. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Application (2016-2021)
    Table 32. Global Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 33. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 34. North America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 35. North America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2022-2027) & (US$ Million)
    Table 36. North America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2021) (US$ Million)
    Table 37. North America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2022-2027) & (US$ Million)
    Table 38. North America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2016-2021) & (US$ Million) 
    Table 39. North America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2022-2027) & (US$ Million) 
    Table 40. Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 41. Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2022-2027) & (US$ Million)
    Table 42. Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2021) (US$ Million)
    Table 43. Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2022-2027) & (US$ Million)
    Table 44. Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2016-2021) & (US$ Million) 
    Table 45. Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2022-2027) & (US$ Million) 
    Table 46. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 47. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2022-2027) & (US$ Million)
    Table 48. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2021) (US$ Million)
    Table 49. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2022-2027) & (US$ Million)
    Table 50. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Region (2016-2021) & (US$ Million) 
    Table 51. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Region (2022-2027) & (US$ Million) 
    Table 52. Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 53. Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2022-2027) & (US$ Million)
    Table 54. Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2021) (US$ Million)
    Table 55. Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2022-2027) & (US$ Million)
    Table 56. Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2016-2021) & (US$ Million) 
    Table 57. Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2022-2027) & (US$ Million) 
    Table 58. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2016-2021) (US$ Million)
    Table 59. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2022-2027) & (US$ Million)
    Table 60. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2016-2021) (US$ Million)
    Table 61. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2022-2027) & (US$ Million)
    Table 62. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2016-2021) & (US$ Million) 
    Table 63. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2022-2027) & (US$ Million) 
    Table 64. Bristol-Myers Squibb Company Details
    Table 65. Bristol-Myers Squibb Business Overview
    Table 66. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Product
    Table 67. Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021) & (US$ Million)
    Table 68. Bristol-Myers Squibb Recent Development
    Table 69. FibroGen (US) Company Details
    Table 70. FibroGen (US) Business Overview
    Table 71. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Product
    Table 72. FibroGen (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021) & (US$ Million)
    Table 73. FibroGen (US) Recent Development
    Table 74. Italfarmaco (Italy) Company Details
    Table 75. Italfarmaco (Italy) Business Overview
    Table 76. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Product
    Table 77. Italfarmaco (Italy) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021) & (US$ Million)
    Table 78. Italfarmaco (Italy) Recent Development
    Table 79. Marathon Company Details
    Table 80. Marathon Business Overview
    Table 81. Marathon Duchenne Muscular Dystrophy Therapeutics Product
    Table 82. Marathon Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021) & (US$ Million)
    Table 83. Marathon Recent Development
    Table 84. NS Pharma (US) Company Details
    Table 85. NS Pharma (US) Business Overview
    Table 86. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Product
    Table 87. NS Pharma (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021) & (US$ Million)
    Table 88. NS Pharma (US) Recent Development
    Table 89. PTC Therapeutics (US) Company Details
    Table 90. PTC Therapeutics (US) Business Overview
    Table 91. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product
    Table 92. PTC Therapeutics (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021) & (US$ Million)
    Table 93. PTC Therapeutics (US) Recent Development
    Table 94. Pfizer Company Details
    Table 95. Pfizer Business Overview
    Table 96. Pfizer Duchenne Muscular Dystrophy Therapeutics Product
    Table 97. Pfizer Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021) & (US$ Million)
    Table 98. Pfizer Recent Development
    Table 99. ReveraGen BioPharma (US) Company Details
    Table 100. ReveraGen BioPharma (US) Business Overview
    Table 101. ReveraGen BioPharma (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021) & (US$ Million)
    Table 102. ReveraGen BioPharma (US) Recent Development
    Table 103. Santhera Pharmaceuticals (Switzerland) Company Details
    Table 104. Santhera Pharmaceuticals (Switzerland) Business Overview
    Table 105. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Product
    Table 106. Santhera Pharmaceuticals (Switzerland) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021) & (US$ Million)
    Table 107. Santhera Pharmaceuticals (Switzerland) Recent Development
    Table 108. Sarepta Therapeutics (US) Company Details
    Table 109. Sarepta Therapeutics (US) Business Overview
    Table 110. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product
    Table 111. Sarepta Therapeutics (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021) & (US$ Million)
    Table 112. Sarepta Therapeutics (US) Recent Development
    Table 113. Research Programs/Design for This Report
    Table 114. Key Data Information from Secondary Sources
    Table 115. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Type: 2020 VS 2027
    Figure 2. Pain Management Drugs Features
    Figure 3. Corticosteroids Features
    Figure 4. Prednisolone Features
    Figure 5. Prednisone Features
    Figure 6. Deflazacort Features
    Figure 7. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Application: 2020 VS 2027
    Figure 8. Hospitals Case Studies
    Figure 9. Clinics Case Studies
    Figure 10. Home Care Case Studies
    Figure 11. Duchenne Muscular Dystrophy Therapeutics Report Years Considered
    Figure 12. Global Duchenne Muscular Dystrophy Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 13. Global Duchenne Muscular Dystrophy Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 14. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Regions: 2020 VS 2027
    Figure 15. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Regions (2022-2027)
    Figure 16. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Players in 2020
    Figure 17. Global Top Duchenne Muscular Dystrophy Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Duchenne Muscular Dystrophy Therapeutics as of 2020
    Figure 18. The Top 10 and 5 Players Market Share by Duchenne Muscular Dystrophy Therapeutics Revenue in 2020
    Figure 19. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Type (2016-2021)
    Figure 20. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Type (2022-2027)
    Figure 21. North America Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 22. North America Duchenne Muscular Dystrophy Therapeutics Market Share by Type (2016-2027)
    Figure 23. North America Duchenne Muscular Dystrophy Therapeutics Market Share by Application (2016-2027)
    Figure 24. North America Duchenne Muscular Dystrophy Therapeutics Market Share by Country (2016-2027)
    Figure 25. United States Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 26. Canada Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 27. Europe Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 28. Europe Duchenne Muscular Dystrophy Therapeutics Market Share by Type (2016-2027)
    Figure 29. Europe Duchenne Muscular Dystrophy Therapeutics Market Share by Application (2016-2027)
    Figure 30. Europe Duchenne Muscular Dystrophy Therapeutics Market Share by Country (2016-2027)
    Figure 31. Germany Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. France Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. U.K. Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Italy Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Russia Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. Nordic Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 37. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 38. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Share by Type (2016-2027)
    Figure 39. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Share by Application (2016-2027)
    Figure 40. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Share by Region (2016-2027)
    Figure 41. China Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. Japan Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. South Korea Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Southeast Asia Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. India Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. Australia Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 47. Latin America Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 48. Latin America Duchenne Muscular Dystrophy Therapeutics Market Share by Type (2016-2027)
    Figure 49. Latin America Duchenne Muscular Dystrophy Therapeutics Market Share by Application (2016-2027)
    Figure 50. Latin America Duchenne Muscular Dystrophy Therapeutics Market Share by Country (2016-2027)
    Figure 51. Mexico Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 52. Brazil Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 53. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 54. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Share by Type (2016-2027)
    Figure 55. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Share by Application (2016-2027)
    Figure 56. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Share by Country (2016-2027)
    Figure 57. Turkey Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 58. Saudi Arabia Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 59. UAE Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 60. Bristol-Myers Squibb Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
    Figure 61. FibroGen (US) Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
    Figure 62. Italfarmaco (Italy) Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
    Figure 63. Marathon Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
    Figure 64. NS Pharma (US) Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
    Figure 65. PTC Therapeutics (US) Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
    Figure 66. Pfizer Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
    Figure 67. ReveraGen BioPharma (US) Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
    Figure 68. Santhera Pharmaceuticals (Switzerland) Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
    Figure 69. Sarepta Therapeutics (US) Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2016-2021)
    Figure 70. Bottom-up and Top-down Approaches for This Report
    Figure 71. Data Triangulation
    Figure 72. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Bristol-Myers Squibb
FibroGen (US)
Italfarmaco (Italy)
Marathon
NS Pharma (US)
PTC Therapeutics (US)
Pfizer
ReveraGen BioPharma (US)
Santhera Pharmaceuticals (Switzerland)
Sarepta Therapeutics (US)
Frequently Asked Questions
Duchenne Muscular Dystrophy Therapeutics report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Duchenne Muscular Dystrophy Therapeutics report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Duchenne Muscular Dystrophy Therapeutics report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports